サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1523252

ホルモン避妊薬市場レポート：2030年までの動向、予測、競合分析

Hormonal Contraceptive Market Report: Trends, Forecast and Competitive Analysis to 2030

出版日
発行
Lucintel
ページ情報
英文 150 Pages
納期
3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

ホルモン避妊薬市場レポート：2030年までの動向、予測、競合分析
出版日: 2024年07月01日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ホルモン避妊薬の動向と予測

世界のホルモン避妊薬市場は、2024年から2030年までのCAGRが3.8%で、2030年までに推定198億米ドルに達すると予想されます。この市場の主な促進要因は、新興経済国におけるホルモン避妊法に関する意識の高まりと、大手企業による新規避妊器具の研究開発への投資の急増です。世界のホルモン避妊薬市場の将来は、ホルモン避妊薬併用市場とプロゲスチンのみの市場に機会があり、有望視されています。

セグメント別のホルモン避妊薬

この調査には、世界のホルモン避妊薬の方法別、ホルモン別、地域別の予測が含まれています。

ホルモン避妊薬市場の洞察

Lucintelでは、ピルに関する認知度の高まりにより、予測期間中ピルが最大セグメントであり続けると予測しています。

この市場の中では、CHCがより大きなセグメントであり続けると思われます。

アジア太平洋地域は、対象人口が多く、主要企業による投資が増加しているため、予測期間中に最も高い成長が見込まれます。

よくある質問

Q1.市場規模は：

A1.世界のホルモン避妊薬市場は、2030年までに推定198億米ドルに達すると予想されています。

Q2.市場の成長予測は：

A2.世界のホルモン避妊薬市場は、2024年から2030年にかけてCAGR 3.8％で成長すると予測されます。

Q3.市場の成長に影響を与える主な促進要因は：

A3.この市場の主な促進要因は、新興経済国におけるホルモン避妊法に関する意識の高まりと、新規避妊器具の研究開発のための大手企業による投資の急増です。

Q4.市場の主要セグメントは：

A4.ホルモン避妊薬市場の将来は、CHC市場とプロゲスチンのみ市場にチャンスがあり、有望です。

Q5.市場の主要企業は：

A5.主なホルモン避妊薬企業は以下の通り：

  • AbbVie
  • Afaxys
  • Teva Pharmaceuticals Industries
  • Bayer
  • Organon
  • Pfizer
  • Agile Therapeutics
  • Janssen Pharmaceutical
  • Lupin Pharmaceutical
  • Pregna International

Q6.今後、最大となる市場セグメントは：

A6.Lucintelは、ピルに関する意識の高まりにより、予測期間中ピルが最大のセグメントであり続けると予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は：

A7.APACは、対象人口が多く、主要企業による投資が増加しているため、予測期間中最も高い成長が見込まれます。

Q8.レポートのカスタマイズは可能か：

A8.はい、Lucintelは追加費用なしで10％のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界のホルモン避妊薬市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界のホルモン避妊薬市場の動向（2018～2023年）と予測（2024～2030年）
  • 方法別の世界のホルモン避妊市場
    • ピル
    • IUD
    • 注射
    • 膣リング
    • インプラント
  • ホルモン別の世界のホルモン避妊薬市場
    • CHC
    • プロゲスチンのみ

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界のホルモン避妊薬市場
  • 北米のホルモン避妊薬市場
  • 欧州のホルモン避妊薬市場
  • アジア太平洋地域のホルモン避妊薬市場
  • その他地域のホルモン避妊薬市場

第5章 競合分析

  • 製品ポートフォリオ分析
  • 運用統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略分析

  • 成長機会分析
  • 世界のホルモン避妊薬市場の新たな動向
  • 戦略分析
    • 新製品の開発
    • 世界のホルモン避妊薬市場の生産能力拡大
    • 世界のホルモン避妊薬市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 主要企業の企業プロファイル

  • AbbVie
  • Afaxys
  • Teva Pharmaceuticals Industries
  • Bayer
  • Organon
  • Pfizer
  • Agile Therapeutics
  • Janssen Pharmaceutical
  • Lupin Pharmaceutical
  • Pregna International
目次

Hormonal Contraceptive Trends and Forecast

The future of the global hormonal contraceptive market looks promising with opportunities in the combination hormonal contraceptive and progestin only markets. The global hormonal contraceptive market is expected to reach an estimated $19.8 billion by 2030 with a CAGR of 3.8% from 2024 to 2030. The major drivers for this market are growing awareness regarding hormonal contraception method in emerging economies and surge in investments by the major players for the R&D of novel contraceptive devices.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Hormonal Contraceptive by Segment

The study includes a forecast for the global hormonal contraceptive by method, hormone, and region.

Hormonal Contraceptive Market by Method [Shipment Analysis by Value from 2018 to 2030]:

  • Pill
  • Intrauterine Device
  • Injectable
  • Vaginal Ring
  • Implant
  • Patch

Hormonal Contraceptive Market by Hormone [Shipment Analysis by Value from 2018 to 2030]:

  • Combination Hormonal Contraceptive
  • Progestin Only

Hormonal Contraceptive Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Hormonal Contraceptive Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies hormonal contraceptive companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the hormonal contraceptive companies profiled in this report include-

  • AbbVie
  • Afaxys
  • Teva Pharmaceuticals Industries
  • Bayer
  • Organon
  • Pfizer
  • Agile Therapeutics
  • Janssen Pharmaceutical
  • Lupin Pharmaceutical
  • Pregna International

Hormonal Contraceptive Market Insights

Lucintel forecasts that pill will remain the largest segment over the forecast period due to increasing awareness about the pills.

Within this market, combination hormonal contraceptive will remain larger segment.

APAC is expected to witness the highest growth over the forecast period due to presence of large pool target population and rise in investment by key players in the region.

Features of the Global Hormonal Contraceptive Market

Market Size Estimates: Hormonal contraceptive market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Hormonal contraceptive market size by method, hormone, and region in terms of value ($B).

Regional Analysis: Hormonal contraceptive market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different methods, hormones, and regions for the hormonal contraceptive market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the hormonal contraceptive market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the hormonal contraceptive market size?

Answer: The global hormonal contraceptive market is expected to reach an estimated $19.8 billion by 2030.

Q2. What is the growth forecast for hormonal contraceptive market?

Answer: The global hormonal contraceptive market is expected to grow with a CAGR of 3.8% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the hormonal contraceptive market?

Answer: The major drivers for this market are growing awareness regarding hormonal contraception method in emerging economies and surge in investments by the major players for the R&D of novel contraceptive devices.

Q4. What are the major segments for hormonal contraceptive market?

Answer: The future of the hormonal contraceptive market looks promising with opportunities in the combination hormonal contraceptive and progestin only markets.

Q5. Who are the key hormonal contraceptive market companies?

Answer: Some of the key hormonal contraceptive companies are as follows:

  • AbbVie
  • Afaxys
  • Teva Pharmaceuticals Industries
  • Bayer
  • Organon
  • Pfizer
  • Agile Therapeutics
  • Janssen Pharmaceutical
  • Lupin Pharmaceutical
  • Pregna International

Q6. Which hormonal contraceptive market segment will be the largest in future?

Answer: Lucintel forecasts that pill will remain the largest segment over the forecast period due to increasing awareness about the pills.

Q7. In hormonal contraceptive market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness the highest growth over the forecast period due to presence of large pool target population and rise in investment by key players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the hormonal contraceptive market by method (pill, intrauterine device, injectable, vaginal ring, implant, and patch), hormone (combination hormonal contraceptive and progestin only), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Hormonal Contraceptive Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Hormonal Contraceptive Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Hormonal Contraceptive Market by Method
    • 3.3.1: Pill
    • 3.3.2: Intrauterine Device
    • 3.3.3: Injectable
    • 3.3.4: Vaginal Ring
    • 3.3.5: Implant
  • 3.4: Global Hormonal Contraceptive Market by Hormone
    • 3.4.1: Combination Hormonal Contraceptive
    • 3.4.2: Progestin Only

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Hormonal Contraceptive Market by Region
  • 4.2: North American Hormonal Contraceptive Market
    • 4.2.1: North American Hormonal Contraceptive Market by Method: Pill, Intrauterine Device, Injectable, Vaginal Ring, Implant, and Patch
    • 4.2.2: North American Hormonal Contraceptive Market by Hormone: Combination Hormonal Contraceptive and Progestin Only
  • 4.3: European Hormonal Contraceptive Market
    • 4.3.1: European Hormonal Contraceptive Market by Method: Pill, Intrauterine Device, Injectable, Vaginal Ring, Implant, and Patch
    • 4.3.2: European Hormonal Contraceptive Market by Hormone: Combination Hormonal Contraceptive and Progestin Only
  • 4.4: APAC Hormonal Contraceptive Market
    • 4.4.1: APAC Hormonal Contraceptive Market by Method: Pill, Intrauterine Device, Injectable, Vaginal Ring, Implant, and Patch
    • 4.4.2: APAC Hormonal Contraceptive Market by Hormone: Combination Hormonal Contraceptive and Progestin Only
  • 4.5: ROW Hormonal Contraceptive Market
    • 4.5.1: ROW Hormonal Contraceptive Market by Method: Pill, Intrauterine Device, Injectable, Vaginal Ring, Implant, and Patch
    • 4.5.2: ROW Hormonal Contraceptive Market by Hormone: Combination Hormonal Contraceptive and Progestin Only

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Hormonal Contraceptive Market by Method
    • 6.1.2: Growth Opportunities for the Global Hormonal Contraceptive Market by Hormone
    • 6.1.3: Growth Opportunities for the Global Hormonal Contraceptive Market by Region
  • 6.2: Emerging Trends in the Global Hormonal Contraceptive Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Hormonal Contraceptive Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Hormonal Contraceptive Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: AbbVie
  • 7.2: Afaxys
  • 7.3: Teva Pharmaceuticals Industries
  • 7.4: Bayer
  • 7.5: Organon
  • 7.6: Pfizer
  • 7.7: Agile Therapeutics
  • 7.8: Janssen Pharmaceutical
  • 7.9: Lupin Pharmaceutical
  • 7.10: Pregna International